Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

34.76
BATS BZX Real-Time Price
As of 9:49am ET
 +0.34 / +0.99%
Today’s Change
30.89
Today|||52-Week Range
59.00
-40.15%
Year-to-Date
Novo Nordisk Files Regulatory Application for Semaglutide
8:51am / Zacks.com - Paid Partner Content
3 High-Yield Dividend Stocks to Buy in December
Nov 30 / MotleyFool.com - Paid Partner Content
Better Buy: MannKind Corp. vs. Novo Nordisk
8:10am / MotleyFool.com - Paid Partner Content
New Strong Sell Stocks for November 28th
Nov 28 / Zacks.com - Paid Partner Content
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
Nov 30 / Zacks.com - Paid Partner Content
Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod
Nov 23 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close34.42
Today’s open34.86
Day’s range34.68 - 34.93
Volume123,406
Average volume (3 months)4,082,865
Market cap$67.5B
Dividend yield2.61%
Data as of 9:49am ET, 12/06/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+8.58%
Revenue growth (last year)+1.43%
P/E ratio2.4
Price/Sales9.38
Price/Book12.83

Competitors

 Today’s
change
Today’s
% change
AZNAstraZeneca+0.13+0.50%
AGNAllergan-0.66-0.35%
LLYEli Lilly and Co+0.04+0.06%
ABTAbbott Laboratories-0.02-0.05%
Data as of 9:49am ET, 12/06/2016

Financials

Next reporting dateFebruary 2, 2017
EPS forecast (this quarter)$0.52
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts


Search for Jobs